News

2015

16 January

Drug research to be strengthened further in the Munich business area:

BEYOND RESEARCH initiative of 4SC Discovery and CRELUX reaches first milestone in drug discovery project for Helmholtz Zentrum München

-       Compounds for inhibiting oxygen radicals and associated signalling pathways optimised for developing innovative therapies for degenerative diseases.

-       Bavarian Ministry of Economic Affairs funding collaboration that will promote the commercial exploitation of a scientific product idea from Helmholtz Zentrum München.

-       BEYOND RESEARCH initiative of 4SC Discovery, CRELUX and Prefound GmbH to provide technology and expertise for transforming drug research from academic institutions into commercially exploitable pharmaceutical products in the Munich area. 

2014

24 July

Project for identifying new bromodomain inhibitors initiated under the Munich m4 biotech cluster programme

 

Planegg-Martinsried, Germany, 24 July 2014 – 4SC AG (Frankfurt, Prime Standard: VSC), a discovery and development company of targeted small molecule drugs for autoimmune diseases and cancer, today announced that its subsidiary 4SC Discovery GmbH, which specialises in the discovery and early-stage research of new substances, has been awarded a research grant for the discovery and identification of new epigenetic anti-cancer compounds in collaboration with its strategic cooperation partner CRELUX GmbH. A joint research project between 4SC Discovery and CRELUX initially running for eleven months will receive funding under the Munich m4 biotech cluster programme. It will focus on the identification of bromodomain inhibitors and their possible later use in personalised medicine. 

2013

8 November

 

AiCuris will use the high quality integrated drug discovery platform i2c of CRELUX and 4SC Discovery to identify novel therapeutics for infectious diseases

Planegg-Martinsried and Wuppertal, Germany, 4 November 2013 – 4SC AG (Frankfurt, Prime Standard: VSC), a discovery and development company of targeted small molecule drugs mainly focusing on cancer and autoimmune diseases, today announced that 4SC Discovery GmbH, CRELUX GmbH and AiCuris GmbH & Co. KG have started a drug discovery collaboration to identify and validate novel small molecule compounds targeting pathogen-specific interactions in infectious diseases. The collaboration is a further proof for the innovative capacity and the high quality standard of the joint integrated drug discovery platform i2c (“idea-to-candidate”), operated by 4SC Discovery and CRELUX. 

12 June

Planegg-Martinsried, Germany and Brussels, Belgium, 11 June 2013 –4SC AG today announced that CRELUX GmbH, 4SC Discovery GmbH and UCB have started a drug discovery collaboration to identify and validate novel small molecule compounds for the treatment of neurological disorders. This collaboration fits perfectly into UCB’s strategy of building a global network of partnerships in order to bring innovative solutions to patients living with severe diseases.

2012

17 June

Planegg-Martinsried, 17June 2012 –The biopharmaceutical company 4SC AG (Frankfurt, Prime Standard: VSC) today announced that its subsidiary 4SC Discovery GmbH, which specialises in the discovery and early-stage research of novel therapeutic compounds, has agreed a research collaboration with Ribological GmbH, Mainz, in the area of compound screening.

18 April

Planegg-Martinsried, 18 April 2012 - The biotech company 4SC AG (Frankfurt, Prime Standard: VSC) announced that its drug discovery affiliate 4SC Discovery GmbH and CRELUX GmbH, a leading company for protein crystallography services, have entered into a strategic partnership for integrated drug discovery services.